<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acquired long QT syndrome: Clinical manifestations, diagnosis, and management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acquired long QT syndrome: Clinical manifestations, diagnosis, and management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acquired long QT syndrome: Clinical manifestations, diagnosis, and management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles I Berul, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Asirvatham, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2156786952">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The long QT syndrome (LQTS) is a disorder of myocardial repolarization characterized by a prolonged QT interval on the electrocardiogram (ECG)  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ). This syndrome is associated with a characteristic life-threatening form of polymorphic ventricular tachycardia known as torsades de pointes (TdP)  (
         <a class="graphic graphic_waveform graphicRef53891 graphicRef73827" href="/z/d/graphic/53891.html" rel="external">
          waveform 2A-B
         </a>
         ).
        </p>
        <p>
         LQTS may be either congenital or acquired. Acquired LQTS usually results from drug therapy  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ), although other factors such as hypokalemia, hypomagnesemia, and bradycardia can increase the risk of drug-induced LQTS.
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of acquired LQTS will be reviewed here. The pathophysiology and causes of acquired LQTS, as well as the clinical manifestations, diagnosis, and management of congenital LQTS, are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/988.html" rel="external">
          "Congenital long QT syndrome: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H181101695">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H3545923122">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acquired LQTS should be suspected in patients who have an ECG that shows a prolonged QTc in the presence of a known QT-prolonging factor(s) such as a medication or electrolyte disturbance. The clinical presentation of acquired LQTS is variable; however, only a minority of patients experience symptoms.
        </p>
        <p class="headingAnchor" id="H2803263656">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of patients are asymptomatic and identified solely by QT prolongation on the ECG. A small minority of patients with acquired LQTS experience an arrhythmia (usually torsades de pointes [TdP]). For these patients, the type and intensity of symptoms will vary depending upon the rate and duration of the TdP and the presence or absence of significant comorbid conditions. While TdP is frequently self-terminating, if the arrhythmia persists, patients may present with sudden cardiac arrest. The definition of TdP is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
         Patients with TdP related to acquired LQTS who notice symptoms typically present with one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presyncope
         </strong>
         – Most commonly, symptomatic patients will be lightheaded or presyncopal and may or may not report palpitations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palpitations
         </strong>
         – These may or may not be related to TdP. These can occur alone or with one or more of the other symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syncope
         </strong>
         –
         <strong>
         </strong>
         Patients presenting with syncope typically have faster and more sustained ventricular arrythmias that lead to hypotension and associated hemodynamic compromise. Patients with syncope do not always have accompanying palpitations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac arrest
         </strong>
         – This results from fast and sustained ventricular arrhythmia and may be a more common presentation in patients with comorbid conditions such as underlying structural or functional heart disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1794169242">
         <span class="h2">
          Unstable presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients present with hemodynamic compromise such as hypotension, altered mental status, chest pain, or heart failure, but they generally remain awake with a discernible pulse. Differentiation between a hemodynamically unstable versus stable patient is detailed separately. (See
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Assessment of hemodynamic stability'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1796953766">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of all patients with suspected acquired LQTS includes a 12-lead ECG and a thorough history, including medications and recent changes in medications, along with bloodwork (this usually includes serum electrolytes, particularly potassium and magnesium, as well as a toxicology screen).
        </p>
        <p class="headingAnchor" id="H1298033160">
         <span class="h2">
          ECG findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected acquired LQTS should have a 12-lead ECG performed, with manual measurement of intervals.
        </p>
        <p class="headingAnchor" id="H1842814899">
         <span class="h3">
          Normal QTc ranges and general ECG principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sinus rhythm QT interval should be measured manually on all available ECGs (including old ECGs for comparison, when available) using multiple leads (preferably leads II and V5) and then corrected for heart rate.
        </p>
        <p>
         The 2011 American Heart Association/American College of Cardiology (AHA/ACC) scientific statement on prevention of torsades de pointes (TdP) in hospital settings recommended that a QTc over the 99th percentile should be considered abnormally prolonged [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The normal range for the rate-corrected QT interval (QTc) is similar in males and females from birth until the start of adolescence, while after puberty and in adults, females have slightly longer QT intervals than males. Before puberty, a QTc &lt;450 ms is considered normal, between 450 and 459 ms is borderline, and ≥460 ms is prolonged. After puberty in males, a QTc between 460 and 469 ms is borderline and ≥470 ms is considered prolonged. In postpubertal females, 460 to 479 ms is borderline and ≥480 ms is considered prolonged. (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis", section on 'QT rate correction'
         </a>
         .)
        </p>
        <p>
         The specific technique of measuring the QT interval, including consideration of U waves and intraventricular conduction delay, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2121.html" rel="external">
          "ECG tutorial: ST and T wave changes", section on 'Prolonged QT interval'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2607687387">
         <span class="h3">
          ECG findings in TdP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical features of TdP include an antecedent prolonged QT interval, particularly in the last heart beat preceding the onset of the arrhythmia. Additional typical features include a ventricular rate of 160 to 250 beats per minute, irregular RR intervals, and a cycling of the QRS axis through 180 degrees every 5 to 20 beats [
         <a href="#rid2">
          2,3
         </a>
         ]. TdP is usually short-lived and typically terminates spontaneously. However, most patients experience multiple episodes of the arrhythmia. These episodes of TdP can recur in rapid succession, potentially degenerating to ventricular fibrillation and sudden cardiac death [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2756320160">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         A careful history is important in diagnosing acquired LQTS since the diagnosis depends on the presence of a QT-prolonging factor. We collect the following history factors in patients with suspected acquired LQTS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – (See
         <a class="local">
          'Symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – This includes the starting date, dose, and duration of use. The medication history should include all drugs (ie, prescription medications [either taken as prescribed or misused], over-the-counter medications, or supplements [including herbal medications]). (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Specific drug regimen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Drugs that prolong the QT interval'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of electrolyte abnormalities
         </strong>
         – Specific factors underlying hypokalemia or hypomagnesemia should be obtained. Examples are recent gastroenteritis or the initiation of diuretic therapy. (See
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney or liver disease
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Metabolic factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Metabolic abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid disease
         </strong>
         –
         <strong>
         </strong>
         The association with LQTS has been described but is not well established [
         <a href="#rid4">
          4
         </a>
         ]. If abnormal thyroid function is found, a second electrolyte or rate-related phenomena (hysteresis) may underlie TdP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothermia
         </strong>
         – This includes accidental and iatrogenic hypothermia from targeted temperature management in patients who have had a postcardiac arrest. (See
         <a class="medical medical_review" href="/z/d/html/178.html" rel="external">
          "Accidental hypothermia in adults", section on 'Electrocardiographic changes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127223.html" rel="external">
          "Intensive care unit management of the intubated post-cardiac arrest adult patient", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127223.html" rel="external">
          "Intensive care unit management of the intubated post-cardiac arrest adult patient", section on 'Electrocardiography and echocardiography'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bradycardia and bradyarrhythmia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Bradyarrhythmias'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history
         </strong>
         – Taking a careful family and genetic history is important because congenital LQTS is important to distinguish from acquired LQTS given differing management strategies. In this regard, screening of family members is also important. (See
         <a class="local">
          'Screening of family members'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of eating disorders such as anorexia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">
          "Anorexia nervosa in adults and adolescents: Medical complications and their management", section on 'Functional changes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3113770476">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basic metabolic panel including serum electrolytes (eg, potassium and magnesium) with liver and kidney function tests should be obtained. If illicit drug or medication misuse is suspected, toxicology testing can be obtained.
        </p>
        <p class="headingAnchor" id="H3116853000">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H889307877">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acquired LQTS can be made in a patient with sufficient QT prolongation on an ECG who is taking a medication or has another cause of QT prolongation (ie, hypokalemia, hypomagnesemia, ischemia, hypothermia). Ideally, the diagnosis is made following review of a full 12-lead ECG. Sometimes a single-lead rhythm strip is adequate if a full 12-lead ECG cannot be obtained. The acquired QT prolongation is typically reversed once the underlying etiology is removed or treated, such as discontinuation of an offending medication or correction of electrolyte derangements.
        </p>
        <p class="headingAnchor" id="H231046796">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main differential diagnosis for acquired LQTS is congenital LQTS. Therefore, a careful family and genetic history is important. Acquired and congenital LQTS may be related since some patients who develop acquired LQTS have an inherited predisposition. Although these patients have abnormalities in repolarization, they do not have enough criteria to meet the definition of congenital LQTS. The diagnosis of congenital LQTS is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4057249808">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with acquired LQTS, we identify and treat any reversible underlying causes of long QT. The management of patients without torsades de pointes (TdP) differs from patients with TdP in terms of urgency of treatment.
        </p>
        <p class="headingAnchor" id="H4291991394">
         <span class="h2">
          All patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cornerstone of the management of patients with acquired LQTS is addressing the underlying cause of QT prolongation. This includes identifying and stopping a precipitating drug(s) and aggressive correction of any metabolic abnormalities, such as hypokalemia or hypomagnesemia [
         <a href="#rid5">
          5
         </a>
         ]. Drugs that prolong the QT interval (see also
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=116011" target="_blank">
          www.crediblemeds.org/
         </a>
         ) should be avoided. These drugs typically inhibit IKr [
         <a href="#rid6">
          6-19
         </a>
         ]. Therefore, in addition to stopping the QT-prolonging drug, correcting hypokalemia is important because a low serum potassium concentration enhances the degree of drug-induced inhibition of IKr, thereby increasing the QT interval [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         For patients with multiple self-terminating episodes of TdP, the same therapies are utilized as for patients with a single episode (ie, intravenous [IV] magnesium, correction of metabolic/electrolyte derangements, and/or removal of any inciting medications), along with additional interventions to regularize the heart rate, which include overdrive atrial pacing and/or IV
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         infusion. Other antiarrhythmics are not commonly used for TdP. Specific therapies used are detailed below.
        </p>
        <p>
         Specific therapy for TdP (the ventricular arrhythmia typically seen in acquired LQTS) differs from congenital LQTS due to pathophysiologic differences between the two forms  (
         <a class="graphic graphic_table graphicRef70083" href="/z/d/graphic/70083.html" rel="external">
          table 2
         </a>
         ). As an example, bradycardia is usually associated with TdP in acquired LQTS, whereas catecholamine surges trigger TdP in some types of congenital LQTS  (
         <a class="graphic graphic_figure graphicRef64239" href="/z/d/graphic/64239.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Triggers of arrhythmia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2233262215">
         <span class="h2">
          Asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient is on a medication that prolongs the QT interval, we make efforts to switch the patient to an alternative agent. If the patient has a strong medical requirement to be on the QT-prolonging medication, if they are truly asymptomatic (eg, no palpitations, presyncope, or syncope), and if they only have mild QT prolongation (QTc &lt;500 ms
         <strong>
          and
         </strong>
         &lt;60 ms increase from baseline, if available) without TdP, we may choose to monitor them in an outpatient setting. Specific protocols for such management have not been established, but we suggest intermittent monitoring with ECGs and Holter recordings, particularly at times of dose changes.
        </p>
        <p>
         Asymptomatic patients with long QT intervals should also have laboratory testing to evaluate for electrolyte abnormalities (eg, potassium, magnesium). Such abnormalities should be corrected as necessary.
        </p>
        <p class="headingAnchor" id="H3527727754">
         <span class="h2">
          Patients with palpitations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of palpitations in a patient with LQTS should be quickly identified with careful history taking and Holter monitoring. If the patient is found to have TdP, management of this malignant arrythmia is discussed below. (See
         <a class="local">
          'Patients with acute TdP'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1895387857">
         <span class="h2">
          Patients with presyncope or syncope
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with prolonged QT with syncope (without documented TdP) or ECG signs of instability (ventricular ectopy, T wave alternans, atrioventricular block, or QRS widening) should be admitted for telemetry observation during withdrawal of the toxic agent (with immediate availability of an external defibrillator) and treatment of arrhythmias if indicated. In addition, admission and monitoring during drug withdrawal is suggested for patients with markedly prolonged QTc (&gt;500 milliseconds) or an increase in QTc of at least 60 milliseconds compared with the predrug baseline value [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3825137218">
         <span class="h2">
          Patients with acute TdP
         </span>
        </p>
        <p class="headingAnchor" id="H3470376351">
         <span class="h3">
          Initial measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TdP should have an immediate assessment of the symptoms, vital signs, and level of consciousness to determine if they are hemodynamically stable or unstable. While the assessment of hemodynamic status is being performed by a clinician, other members of the healthcare team should to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attach the patient to a continuous cardiac monitor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Establish IV access
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain a 12-lead ECG
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer supplemental oxygen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Send blood for appropriate initial studies
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3423199604">
         <span class="h4">
          Unstable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In unstable patients, emergency management is required  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 1
         </a>
         ), and treatment should be promptly administered  (
         <a class="graphic graphic_algorithm graphicRef140279" href="/z/d/graphic/140279.html" rel="external">
          algorithm 2
         </a>
         ). In parallel, underlying etiology and treatment for precipitating factors should be determined. (See
         <a class="local">
          'Unstable presentation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H848292919">
         <span class="h4">
          Stable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TdP who are initially stable may rapidly become unstable, particularly in the setting of extremely rapid heart rates (greater than 200 beats per minute) or significant underlying cardiac comorbidities. Emergency management should be anticipated in these patients in case it becomes necessary to rapidly deliver it. Such patients should remain in a monitored setting during evaluation and management.
        </p>
        <p class="headingAnchor" id="H1759633909">
         <span class="h3">
          Magnesium therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with TdP, IV
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         is first-line therapy since it is highly effective for both the treatment and prevention of recurrence of long QT-related ventricular ectopic beats or TdP [
         <a href="#rid2">
          2,3,20
         </a>
         ]. We usually administer this prior to cardioversion, but it can also be given afterwards. Evidence supporting the specific timing of magnesium is lacking. Treatment with magnesium is effective even without shortening of the QT interval and is beneficial even in patients with normal serum magnesium concentrations at baseline. The rate of magnesium infusion is slower when the patient has a pulse, as rapid magnesium infusion can cause hypotension and asystole.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults with TdP and pulse
         </strong>
         – The standard regimen for an adult is a 1 to 2 g IV bolus of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         (2 to 4 mL of 50% solution [500 mg/mL]) mixed with D5W to a total volume of 10 mL or more (eg, 50 to 100 mL over 15 minutes) [
         <a href="#rid20">
          20,21
         </a>
         ]. If no response is seen or TdP recurs, the magnesium sulfate dose may be repeated immediately to a total of 4 grams in one hour. Use of continuous infusion (as an adjunct to bolus dosing) varies among clinicians. Some clinicians administer a continuous infusion of 0.5 to 1 g/hour (8 to 16 mg/min) if TdP persists after one or more bolus doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults with TdP and no pulse
         </strong>
         – Magnesium is administered in conjunction with electrical cardioversion/defibrillation. A dose of 1 to 2 g
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         (2 to 4 mL of 50% solution [500 mg/mL]) is diluted in 10 mL D5W and administered as a bolus over one to two minutes; the intraosseous route is used if IV is not available. If Tdp recurs or the QTc remains prolonged, some experts administer up to two additional 2 g bolus doses as needed (total maximum dose of 6 g).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – The bolus dose in children is 25 to 50 mg/kg; there are no published data on IV maintenance dosing in children.
        </p>
        <p>
        </p>
        <p>
         For patients with a single episode of TdP, treatment with IV magnesium along with correction of metabolic/electrolyte derangements and/or removal of any inciting medications may be sufficient. The patient should be carefully monitored until electrolytes are normalized and the QT interval nearly normalizes.
        </p>
        <p class="headingAnchor" id="H1506939193">
         <span class="h3">
          Patients who do not respond to magnesium
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pacing
         </strong>
         – For patients with long QT related TdP who do not respond to IV magnesium, we use temporary transvenous overdrive pacing (atrial or ventricular) [
         <a href="#rid2">
          2,3
         </a>
         ]. In patients with a pre-existing permanent pacemaker, we may reprogram the device to increase the pacing rate. In patients with a pre-existing implantable cardioverter-defibrillator (ICD), we may have the ICD reprogrammed to a prolonged detection time, thereby delaying ICD shock for episodes of TdP that may self-terminate. When the patient is stabilized with the temporary wire, we lower the pacing rate and watch for any return of TdP. Usually, the temporary wire will not be needed for longer than one to two days. If the patient requires temporary pacing in order to suppress TdP for longer than two days, this is usually an indication that the patient will need a permanent pacemaker.
        </p>
        <p>
        </p>
        <p>
         Only in rare circumstances, if transvenous pacing is not readily available, transcutaneous pacing may be performed as a temporizing measure. However, the patient must be fully sedated, as transcutaneous pacing is very painful in a patient who is awake.
        </p>
        <p class="bulletIndent1">
         For children over age 5 and adults, pacing at rates of approximately 100 beats per minute will decrease the dispersion of refractoriness, decrease the development of early afterdepolarizations, and may shorten the surface QT interval, especially if there is an associated bradycardia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of overdrive pacing was illustrated in a report of nine patients with life-threatening ventricular arrhythmias and drug-induced LQTS [
         <a href="#rid22">
          22
         </a>
         ]. Acceleration of the heart rate produced immediate suppression of all arrhythmias, with a reduction in the QT interval from 0.65 to 0.50 seconds. Similar findings were noted in another small series [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          Isoproterenol
         </a>
         <strong>
         </strong>
         – Although we favor placement of a temporary pacemaker in the treatment of most cases of TdP that do not respond to magnesium, isoproterenol can be used as a temporizing measure prior to pacing. Isoproterenol increases the sinus rate and decreases the QT interval [
         <a href="#rid2">
          2,3,24
         </a>
         ]. It should be noted that if ventricular tachycardia is misdiagnosed as TdP, isoproterenol will worsen the ventricular tachycardia by increasing the heart rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial dose of
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         is 0.05 to 0.1 mcg/kg/min in children and 2 mcg/min in adults, then titrated to achieve a heart rate of 100 beats per minute.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2635744925">
         <span class="h3">
          Other therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alkalinization of the plasma via the administration of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         is useful when TdP is due to
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">
          "Major side effects of class I antiarrhythmic drugs", section on 'Cardiovascular toxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/325.html" rel="external">
          "Enhanced elimination of poisons", section on 'Urinary alkalinization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1188180581">
         <span class="h3">
          Therapies with less evidence supporting their use
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potassium
         </strong>
         – In a single study, an IV infusion of potassium was shown to be beneficial even in patients with normal serum potassium. This was illustrated in a report of 20 normokalemic patients with QT prolongation due to
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         or heart failure [
         <a href="#rid26">
          26
         </a>
         ]. The administration of IV potassium (0.5 mEq/kg to a maximum of 40 mEq) raised the plasma potassium concentration by 0.7 mEq/L, reversed QT prolongation and QT morphologic changes (U waves and bifid T waves), and decreased QT dispersion. It is uncertain, however, if this therapy is effective for preventing or reversing TdP; therefore, we reserve using these medications for selected patients with clinically refractory TdP and would not give IV potassium if the serum level was in the normal range.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Class IB antiarrhythmic drugs
         </strong>
         –
         <strong>
         </strong>
         Medications such as
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         shorten the action potential duration and, based upon small case series, may be effective in the acute management of TdP and ventricular fibrillation [
         <a href="#rid27">
          27-31
         </a>
         ]. They appear to be less predictably effective than pacing or
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         [
         <a href="#rid3">
          3,27
         </a>
         ]. Therefore, we reserve using these medications for selected patients with clinically refractory TdP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2716076437">
         <span class="h1">
          LONG-TERM MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acquired LQTS should be educated about the culprit drugs, other QT-prolonging drugs (including being provided with a list, available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=116011" target="_blank">
          www.crediblemeds.org/
         </a>
         ), and potential drug-drug interactions [
         <a href="#rid1">
          1
         </a>
         ]. Additional information can also be found using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         . In some patients, drug-associated LQTS appears to represent a concealed form of congenital LQTS in which a pathogenic variant in one of the LQTS genes is clinically inapparent until the patient is exposed to a particular drug or other predisposing factor (eg, hypokalemia or hypomagnesemia). If appropriate, the patient should be referred for genetic testing. (See
         <a class="medical medical_review" href="/z/d/html/1009.html" rel="external">
          "Congenital long QT syndrome: Pathophysiology and genetics"
         </a>
         .)
        </p>
        <p>
         A permanent pacemaker may be required in the occasional patient with a chronic bradyarrhythmia (due to sinus node dysfunction or atrioventricular block) who has bradycardia- or pause-dependent TdP  (
         <a class="graphic graphic_table graphicRef80487" href="/z/d/graphic/80487.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/941.html" rel="external">
          "Permanent cardiac pacing: Overview of devices and indications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2447343820">
         <span class="h1">
          PROGNOSIS OF TDP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with TdP, the in-hospital and one-year mortality rates are relatively high. In a nested case control study from a genetics cohort of over 110,000 patients from an integrated health system, 56 patients with TdP were studied; their in-hospital and one-year mortality rates were 11 and 25 percent, respectively [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1185028559">
         <span class="h1">
          SCREENING OF FAMILY MEMBERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to treating the underlying cause, thorough history and ECG screening of immediate family members are recommended because of the potential for unmasking an inherited form and, therefore, the potential for other family members to harbor mutations causing congenital LQTS. (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Underlying pathogenic variant in a long QT syndrome gene'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1383902205">
         <span class="h1">
          PRECAUTIONS FOR ANY PATIENT STARTING QT-PROLONGING DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For any patient who is treated with drugs that have been associated with LQTS  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ) (see also
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=116011" target="_blank">
          www.crediblemeds.org/
         </a>
         ), the following recommendations have been made [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Caution should be used when prescribing a drug that prolongs the QT interval in patients with one or more risk factors (eg, diuretic therapy, electrolyte abnormalities, kidney disease, etc). Decisions regarding use of a QT-prolonging drug should be based upon an individualized risk-benefit analysis. Alternative agents that do not prolong the QT interval should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of more than one QT-prolonging drug should be avoided whenever possible, as this is a common risk factor for drug-induced TdP. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Risk factors for drug-induced long QT syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECG monitoring
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A baseline ECG to detect prolongation of the QT interval should be obtained prior to the administration of the drug and during the course of treatment. The 2011 American Heart Association/American College of Cardiology (AHA/ACC) scientific statement on prevention of TdP suggests a strategy of documenting the QTc interval before and at least every 8 to 12 hours after the initiation, increased dose, or overdose of QT-prolonging drugs [
         <a href="#rid1">
          1
         </a>
         ]. If QTc prolongation is observed, more frequent measurements are recommended. (See
         <a class="local">
          'ECG findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The duration of QTc monitoring depends upon the duration of treatment with the QT-prolonging drug and the drug half-life. Once the patient is on a steady state of the drug, an ECG should be done to measure their QTc.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Educating patients
         </strong>
         – Patients who are taking QT-prolonging drugs should be instructed to promptly report any new symptoms including palpitations, syncope, or near-syncope. They should also report clinical changes that could lead to hypokalemia, such as gastroenteritis or the initiation of diuretic therapy. Any identified electrolyte abnormalities should be promptly corrected in order to minimize the risk of arrhythmias.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2385978287">
         <span class="h1">
          TDP DECISION SUPPORT TOOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         A study showed that a clinical decision support tool programmed to appear when prescribers attempt to order medications for patients with risk factors for TdP may help identify high-risk patients and lead to clinical responses that could potentially prevent TdP [
         <a href="#rid34">
          34
         </a>
         ]. The decision support tool was embedded in the electronic medical record system of a large healthcare system in 30 hospitals. The tool included a risk advisory that was programmed to appear when prescribers attempted to order medications with a known risk of TdP in such patients with a modified Tisdale QT risk score ≥12 (The modified Tisdale is a validated TdP risk score based on patient demographic and clinical and ECG characteristics) [
         <a href="#rid35">
          35
         </a>
         ]. The advisory presented the clinician with the patient's QT risk score, delineated factors contributing to the score, and then presented relevant single‐click management options. Over an eight-month period, 7794 advisories were issued. The study reported the following findings with respect to risk advisories issued:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibiotics most frequently triggered the advisory (in 33 percent of advisories).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More than one management action was taken for 35 percent of the advisories.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common action was ordering an ECG (in 20 percent of all advisories).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medication orders were canceled in 10 percent of patients with an advisory.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1801806834">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116416.html" rel="external">
          "Society guideline links: Inherited arrhythmia syndromes"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">
          "Society guideline links: Ventricular arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2191323780">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86973.html" rel="external">
          "Patient education: Long QT syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3032750045">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Acquired long QT syndrome (LQTS) is a disorder of myocardial repolarization characterized by a prolonged QT interval on the electrocardiogram (ECG)  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ). It usually results from drug therapy, hypokalemia, and/or hypomagnesemia  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – The clinical presentation of acquired LQTS is variable; many patients are asymptomatic and identified solely by QT prolongation on the ECG, while a minority are symptomatic and present with presyncope, palpitations, syncope, and/or sudden cardiac arrest. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The evaluation of all patients with suspected acquired LQTS includes a 12-lead ECG, a thorough history, and laboratory testing. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The history should include medications, recent medications changes, kidney or liver dysfunction symptoms, family history, and bloodwork (See
         <a class="local">
          'History'
         </a>
         above and
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of acquired LQTS can be made in a patient with sufficient QT prolongation on the surface ECG in association with a medication or other clinical scenario (ie, hypokalemia or hypomagnesemia). In general, the cutpoints for abnormal QTc are the 99th percentile QTc values (470 ms in postpubertal males and 480 ms in postpubertal females). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precautions when starting a QT-prolonging medication
         </strong>
         – It may be necessary to obtain a baseline and follow-up QT interval. We educate the patient on potential symptoms and ask them to report the symptoms should they arise. (See
         <a class="local">
          'Precautions for any patient starting QT-prolonging drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of patients without active torsades de pointes (TdP)
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic patients
         </strong>
         – In such patients, we identify and treat any reversible underlying causes of long QT such as electrolyte disturbances and kidney or hepatic dysfunction. Any QT-prolonging medications should be stopped. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palpitations
         </strong>
         – In such patients, the cause of palpitations should be quickly identified with careful history taking and Holter monitoring. If the patient is found to have TdP, management of this malignant arrythmia is discussed elsewhere. (See
         <a class="local">
          'Patients with palpitations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Syncope
         </strong>
         – If there is presyncope or syncope (without documented TdP) or ECG signs of instability (ventricular ectopy, T wave alternans, atrioventricular block, or QRS widening), the patient should be admitted for telemetry observation during withdrawal of the toxic agent (with immediate availability of an external defibrillator) and treatment of arrhythmias if indicated. (See
         <a class="local">
          'Patients with presyncope or syncope'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of patients with acute TdP
         </strong>
         – The initial management of patients with TdP varies depending on the hemodynamic stability of the patient. Emergency management is required in unstable patients  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 1
         </a>
         ), while additional time may be spent determining the etiology and treating any underlying precipitating factors in patients who are hemodynamically stable  (
         <a class="graphic graphic_algorithm graphicRef140279" href="/z/d/graphic/140279.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Patients with acute TdP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically unstable patients
         </strong>
         – These patients are generally severely symptomatic or become pulseless. They require prompt emergency treatment  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 1
         </a>
         ). Initial treatment with antiarrhythmic medications, with the exception of intravenous (IV) magnesium, is not indicated for hemodynamically unstable or pulseless patients. Subsequent therapy is similar to that of hemodynamically stable patients with TdP. (See
         <a class="local">
          'Unstable patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically stable patients
         </strong>
         – These patients may become unstable rapidly and without warning. As such, therapy should be promptly provided to most patients. Initial therapy for patients with a single episode of TdP is IV magnesium along with correction of metabolic/electrolyte derangements and/or removal of any inciting medications. For patients with subsequent, multiple, self-terminating episodes of TdP, we use the same therapies as for patients with a single episode, along with additional interventions to slow the heart rate. These include overdrive atrial pacing and/or IV
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         infusion. (See
         <a class="local">
          'Initial measures'
         </a>
         above and
         <a class="local">
          'Patients who do not respond to magnesium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term management
         </strong>
         – Patients with acquired LQTS should be educated about the culprit drugs, other QT-prolonging drugs (including being provided with a list, available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=116011" target="_blank">
          www.crediblemeds.org/
         </a>
         ), and potential drug-drug interactions. (See
         <a class="local">
          'Long-term management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2984175543">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Stephen Seslar MD, PhD, and the late Mark E. Josephson, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 2001; 85:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan IA. Long QT syndrome: diagnosis and management. Am Heart J 2002; 143:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannan L, Kotus-Bart J, Amanullah A. Prevalence of Cardiac Arrhythmias in Hypothyroid and Euthyroid Patients. Horm Metab Res 2017; 49:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupershmidt S, Yang IC, Hayashi K, et al. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J 2003; 17:2263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridley JM, Milnes JT, Benest AV, et al. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide. Biochem Biophys Res Commun 2003; 306:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993; 72:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995; 91:1799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numaguchi H, Mullins FM, Johnson JP Jr, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001; 103:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 91:3010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998; 286:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiSegni E, Klein HO, David D, et al. Overdrive pacing in quinidine syncope and other long QT-interval syndromes. Arch Intern Med 1980; 140:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tötterman KJ, Turto H, Pellinen T. Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). Acta Med Scand Suppl 1982; 668:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 1981; 64:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WASSERMAN F, BRODSKY L, KATHE JH, et al. The effect of molar sodium lactate in quinidine intoxication. Am J Cardiol 1959; 3:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assimes TL, Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol 1998; 14:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi N, Ito M, Inoue T, et al. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases. J Cardiol 1993; 23:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raehl CL, Patel AK, LeRoy M. Drug-induced torsade de pointes. Clin Pharm 1985; 4:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vukmir RB, Stein KL. Torsades de pointes therapy with phenytoin. Ann Emerg Med 1991; 20:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantri N, Lu M, Zaroff JG, et al. Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. Ann Noninvasive Electrocardiol 2022; 27:e12888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallo T, Heise CW, Woosley RL, et al. Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. J Am Heart Assoc 2022; 11:e024338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013; 6:479.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 116011 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142454" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11233951" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773906" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Long QT syndrome: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28472829" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of Cardiac Arrhythmias in Hypothyroid and Euthyroid Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9604234" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Taking the "idio" out of "idiosyncratic": predicting torsades de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525949" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565156" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804575" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8417848" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7882490" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090546" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238279" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7796513" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065733" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772706" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8641472" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445174" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9694927" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Blockade of HERG and Kv1.5 by ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3338130" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of torsade de pointes with magnesium sulfate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956224" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7396607" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Overdrive pacing in quinidine syncope and other long QT-interval syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6963090" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7296791" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13626863" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The effect of molar sodium lactate in quinidine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9337183" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Normalization of acquired QT prolongation in humans by intravenous potassium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3716982" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9627533" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Torsade de pointes with sotalol overdose treated successfully with lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8164140" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2416504" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Drug-induced torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1996806" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Torsades de pointes therapy with phenytoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34547155" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Torsade de pointes: A nested case-control study in an integrated healthcare delivery system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14999113" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Drug-induced prolongation of the QT interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35656987" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23716032" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
